


Veenstra  
Appl. No. 10/527,518

### Listing of Claims


This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (previously presented) A compound of the formula



wherein Y is =N- or =N(O)-, R is OH when Y is =N- and R is H when Y is =N(O)- and the ring A is unsubstituted or mono- or poly-substituted by substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, provided that when R is OH and Y is =N- the ring A is not unsubstituted, and pharmaceutically acceptable salts thereof.

2. (previously presented) A compound according to claim 1 of formula 1A



wherein Y is =N- or =N(O)-, R is OH when Y is =N- and R is H when Y is =N(O)-, and Z is hydrogen, halogen or nitro, provided that when R is OH and Y is =N- Z is not H, and pharmaceutically acceptable salts thereof.


Veenstra  
Appl. No. 10/527,518

3. (previously presented) A compound according to claim 2, wherein Y is =N- or =N(O)-, R is OH when Y is =N- and R is H when Y is =N(O)-, and Z is halogen.
4. (previously presented) The compounds (2R,4S)-N-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-piperidin-4-yl]-quinoline-N-oxide-4-carboxamide or a pharmaceutically acceptable salt thereof, or (2R,4S)-N-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-piperidin-4-yl]-3-hydroxy-quinoline-4-carboxamide or a pharmaceutically acceptable salt thereof.
5. (currently amended) A method of treating a condition characterized by substance-P induction, in administering a therapeutically effective amount of a compound of formula 1 to an animal in need thereof to treat the following disorders induced by substance P: pain; migraines; anxiety; vomiting; schizophrenia; depression; motor disorders such as Parkinson's disease; inflammatory diseases such as rheumatoid arthritis, iritis and conjunctivitis; diseases of the respiratory organs such as asthma and chronic bronchitis; diseases of the gastrointestinal system such as ulcerative colitis and Crohn's disease; and hypertension comprising: administering an amount of substance-P antagonist effective to inhibit the induction of substance-P, wherein the substance-P antagonist is a compound according to Claim 1.
6. (previously presented) A pharmaceutical composition comprising a compound according to claim 1.
7. (cancelled)

Veenstra  
Appl. No. 10/527,518

8. (currently amended) A process for the preparation of a compound of Formula I,  
~~which comprisesing:~~

oxidising a compound of formula II;



optionally separating a mixture of isomers obtainable by the process; and  
isolating the desired isomer of the resulting oxidized compound.